Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors

被引：0
|
作者：
Larry K. Golightly
Caitlin C. Drayna
Michael T. McDermott
机构：
[1] University of Colorado Hospital,Division of Endocrinology, Metabolism, and Diabetes
[2] University of Colorado Hospital Center for Drug Information,Medication Use Evaluation/Adverse Drug Reaction Coordinator
[3] Education,undefined
[4] and Evaluation,undefined
[5] University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences,undefined
[6] University of Colorado School of Medicine,undefined
[7] University of Colorado Hospital,undefined
[8] Anschutz Medical Campus Box A-003,undefined
[9] Health Sciences Library/Center for Drug Information,undefined
[10] Education,undefined
[11] and Evaluation,undefined
来源：
Clinical Pharmacokinetics | 2012年 / 51卷 / 8期
关键词：
Sitagliptin; Vildagliptin; Severe Renal Impairment; Saxagliptin; Linagliptin;
D O I：
10.1007/BF03261927
中图分类号：
学科分类号：
摘要：
Dipeptidyl peptidase-4 (DPP-4) inhibitors collectively comprise a presently unique form of disease management for persons with type 2 diabetes mellitus. The aim of this review is to compare the clinical pharmacokinetics of available DPP-4 inhibitors (alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin) for the purpose of identifying potential selection preferences according to individual patient variables and co-morbidities.
引用
收藏
页码：501 / 514
页数：13
相关论文
共 50 条
  • [1] Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
    Golightly, Larry K.
    Drayna, Caitlin C.
    McDermott, Michael T.
    CLINICAL PHARMACOKINETICS, 2012, 51 (08) : 501 - 514
  • [2] Erratum to: Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
    Larry K. Golightly
    Caitlin C. Drayna
    Michael T. McDermott
    Clinical Pharmacokinetics, 2012, 51 : 831 - 831
  • [3] Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors (vol 51, pg 501, 2012)
    Golightly, Larry K.
    Drayna, Caitlin C.
    McDermott, Michael T.
    CLINICAL PHARMACOKINETICS, 2012, 51 (12) : 831 - 831
  • [4] Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas
    Deacon, C. F.
    Lebovitz, H. E.
    DIABETES OBESITY & METABOLISM, 2016, 18 (04): : 333 - 347
  • [5] Dipeptidyl peptidase-4 inhibitors -: Clinical data and clinical implications
    Ahren, Bo
    DIABETES CARE, 2007, 30 (06) : 1344 - 1350
  • [6] Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor
    Boulton, David W.
    CLINICAL PHARMACOKINETICS, 2017, 56 (01) : 11 - 24
  • [7] Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor
    David W. Boulton
    Clinical Pharmacokinetics, 2017, 56 : 11 - 24
  • [8] Dipeptidyl peptidase-4 inhibitors and osteoporosis
    Lee, Wen-Ling
    Lee, Fa-Kung
    Wang, Peng-Hui
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2022, 85 (09) : 889 - 890
  • [9] The role of dipeptidyl peptidase-4 inhibitors
    Lasserson, Daniel
    Mant, Jonathan
    BRITISH MEDICAL JOURNAL, 2012, 344
  • [10] Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment
    Davis, T. M. E.
    DIABETES OBESITY & METABOLISM, 2014, 16 (10): : 891 - 899
12345